Galectin Therapeutics (NASDAQ:GALT) Stock Passes Above 200-Day Moving Average - Should You Sell?

Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.64 and traded as high as $3.35. Galectin Therapeutics shares last traded at $3.30, with a volume of 378,476 shares.

Analysts Set New Price Targets

GALT has been the topic of a number of research analyst reports. HC Wainwright initiated coverage on Galectin Therapeutics in a research report on Tuesday, June 17th. They set a "buy" rating and a $6.00 target price on the stock. Wall Street Zen raised Galectin Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, June 21st.

Galectin Therapeutics Trading Up 0.3%

The firm's 50 day moving average is $2.25 and its two-hundred day moving average is $1.69. The stock has a market cap of $231.02 million, a price-to-earnings ratio of -5.07 and a beta of 0.70.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.05. As a group, equities analysts expect that Galectin Therapeutics Inc. will post -0.73 EPS for the current fiscal year.

Hedge Funds Weigh In On Galectin Therapeutics

Several institutional investors have recently added to or reduced their stakes in GALT. HighTower Advisors LLC acquired a new stake in Galectin Therapeutics during the fourth quarter worth about $29,000. LPL Financial LLC increased its stake in Galectin Therapeutics by 69.6% during the fourth quarter. LPL Financial LLC now owns 138,928 shares of the company's stock worth $179,000 after acquiring an additional 57,020 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Galectin Therapeutics by 94.9% during the fourth quarter. JPMorgan Chase & Co. now owns 59,693 shares of the company's stock worth $77,000 after acquiring an additional 29,065 shares during the last quarter. Geode Capital Management LLC increased its stake in Galectin Therapeutics by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 870,589 shares of the company's stock worth $1,124,000 after acquiring an additional 8,047 shares during the last quarter. Finally, Barclays PLC increased its stake in Galectin Therapeutics by 91.1% during the fourth quarter. Barclays PLC now owns 54,634 shares of the company's stock worth $71,000 after acquiring an additional 26,047 shares during the last quarter. 11.68% of the stock is currently owned by institutional investors and hedge funds.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.